Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data

Rheumatology

Volumn 42, Issue 11, 2003, Pages 1332-1341

  Layton, Deborah ^a,b   Hughes, K ^a   Harris, S ^a,c   Shakir, S A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adverse events; Celecoxib; COX 2 selective inhibitors; Drug safety; Meloxicam; Prescription event monitoring

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; AGE; AGED; ANAMNESIS; ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DRUG INDICATION; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DUODENITIS; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; ESOPHAGUS ULCER; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GENDER; GENERAL PRACTICE; GENERAL PRACTITIONER; HEARTBURN; HIATUS HERNIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OSTEOARTHRITIS; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; STOMACH ULCER; SYMPTOM; UNITED KINGDOM;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; ENGLAND; FAMILY PRACTICE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOARTHRITIS; POISSON DISTRIBUTION; PYRAZOLES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONAMIDES; THIAZINES; THIAZOLES;

EID: 0242472760     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg376     Document Type: Article

References (37)

1. National Institute of Clinical Excellence. Guidance on use of cyclo-oxygenase (COXII) selective inhibitors celecoxib, rofecoxib, meloxicam and etodoloac for osteoarthritis and rheumatoid arthritis. Technology Appraisal No.27. London: Department of Health, 2001.
2. Layton D, Heeley E, Hughes K, Shakir S. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 2003;42:622-31.
3. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J Am Med Assoc 1999;282:1921-8.
4. Emery P, Zeidler H, Kvien TK et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
5. Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
6. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000;284:1247-55.
7. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
8. Panara MR, Renda G, Sciulli MG et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 1999;290:276-80.
9. Noble S, Balfour JA. Meloxicam. Drugs 1996;51:424-30.
10. Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51.
11. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8.
12. Singh G, Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal complications; pooled analysis of 27 039 patients. [Abstract No. OP0085.] European Congress of Rheumatology, Prague, 2001. www.eular.org
13. Mann RD. Prescription-event monitoring - recent progress and future horizons. Br J Clin Pharmacol 1998;46:195-201.
14. Legemaate J. The CIOMS guidelines for biomedical research involving human subjects. Eur J Health Law 1994;1:161-5.
15. Royal College of Physicians of London. Guidelines on the practice of Ethical Committees in Medical Research involving Human Subjects. London: 1996.
16. Multi-Centre Research Ethics Committees Guidance Notes. Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary. Appendix C, 19, 19 October 2000. http://www.corec.org.uk/wordDocs/Guidenotes.doc
17. Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19 087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000;50:35-42.
18. Mann RD, Rawlins MD, Fletcher P. Age and the spontaneous reporting of adverse reactions in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1:19-23.
19. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120:594-606.
20. Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997;26:16-20.
21. MacDonald TM, Morant SV, Robinson GC et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. Br Med J 1997;315:1333-7.
22. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
23. Lanes S, Garcia Rodriguez LA, Hwang E. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin. Pharmacoepidemiol Drug Saf 2002;9:113-7.
24. Layton D, Riley J, Wilton LW, Shakir S. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2002;55:166-74.
25. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-6.
26. Searle/Pfizer. Summary of Product Characteristics: Celebrex (celecoxib) May 2000.
27. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35(Suppl. 1):68-77.
28. Kaplan-Machlis B, Klostermeyer BS. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother 1999;33:979-88.
29. Blain H, Boileau C, Lapicque F et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 2002;53:255-65.
30. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Br Med J 2002;324:1287-8.
31. Shakir SA. PEM in the UK. In: Mann RD, Andrews E, eds. Pharmacovigilance. Chichester, UK: John Wiley & Sons, 2002:333-44.
32. Hawkey CJ. Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. Am J Med 1998;104:67S-74S.
33. Scottish Intercollegate Guidelines Network. Helicobacter pylori eradication in dyspeptic disease. Edinburgh: SIGN, 1996.
34. Mackay F, Dunn NR, Wilton LW, Mann RD. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997;6:235-46.
35. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 1529, 1530.
36. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Br Med J 2002; 325:619.
37. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br Med J 2002;325:624.